Programme Groupings. For 2013, the preliminary molecular external quality assessment (EQA) programme schedule has been displayed by Disease Group.
|
|
|
- Britney Walker
- 6 years ago
- Views:
Transcription
1 Equalis EQA s 2013 Preliminary Schedule For 2013, the preliminary molecular external quality assessment (EQA) programme schedule has been displayed by Disease Group. Note: EQA programmes may appear in more than one group. This has been indicated by the following icons appearing next to the relevant programme names. Disease Group Key Disease Group Colour Icon Blood Borne Virus Central Nervous System Congenital Infection Drug Resistance Exotic Gastro Immunocompromised Respiratory Sexually Transmitted infection Transplant Typing QCMD EQA Pilot Studies 2013 A number of new EQA pilot studies may be introduced throughout 2013, and registration for these will be announced approximately 8 weeks prior to their EQA panel distribution. If you have requirements which are not supported by our current EQA offering, please contact the QCMD team (info@qcmd.org) for information about QCMD pilot studies. New EQA Pilot Studies are show as QCMD Regulatory EQAs in the groupings The regulatory EQA format will comprise of four challenges per year: Two full EQA panels (8-10 panel members) and two core EQA panels consisting of 4 panel members. The focus of these EQAs is on quantitative detection, and following each EQA challenge online reporting will enable participating labs to monitor their cumulative performance over time. NB: Registering for a Regulatory EQA will automatically subscribe you to the A & B EQAs for the selected pathogen. PreSh13-EQUALIS02 5 Technology Terrace, Todd Campus West of Scotland Science Park Glasgow, G20 0XA, Scotland Tel: +44 (0) , Fax: +44 (0) info@qcmd.org, Web: Page 1 of 8
2 Blood Borne Virus QAV HIVDNA13A HIV-1 (DNA) Q1 Dry-ice QAV B19DNA13 B19 Virus Q1 Dry-ice QAV HCVGT13 HCV Genotyping Q1 Dry-ice QAV HBVGT13 HBV Genotyping Q1 Dry-ice QAV ENVA13 HIV-1 Drug Resistance Q3 Ambient QAV ENVAINT13 HIV-1 Drug Resistance (Integrase) Q3 Ambient QAV HIVDNA13B HIV-1 (DNA) Q3 Dry-ice QAV HAVRNA13 Hepatitis A virus Q3 Dry-ice QAV HEVRNA13 Hepatitis E virus Q3 Dry-ice QAV HBVDR13 HBV Drug Resistance Q3 Dry-ice QAV HCVDR13 HCV Drug Resistance Q3 Dry-ice HIV RNA EQA Range QAV HIVRNA13A HIV-1 (RNA) Q1 Dry-ice QAV HIVRNA13B HIV-1 (RNA) Q3 Dry-ice QAV HIVRNAReg13 HIV-1 RNA regulatory programme (4 distributions per year) Q1-4 Dry-ice HBV RNA EQA Range QAV HBVDNA13A Hepatitis B virus Q1 Dry-ice QAV HBVDNA13B Hepatitis B virus Q3 Dry-ice QAV HBVDNAReg13 HBV regulatory programme (4 distributions per year) Q1-4 Dry-ice HCV RNA EQA Range QAV HCVRNA13A Hepatitis C virus Q1 Dry-ice QAV HCVRNA13B Hepatitis C virus Q3 Dry-ice QAV HCVRNAReg13 HCV regulatory programme (4 distributions per year) Q1-4 Dry-ice Page 2 of 8
3 Central Nervous System QAV VZVDNA13 Varicella-Zoster virus Q1 Ambient QAV EVRNA13 Enterovirus Q1 Ambient QAV PeVRNA13 Parechovirus Q1 Ambient QAV HSVDNA13 Herpes simplex virus 1& 2 Q1 Ambient QAV WNVRNA13 West Nile Virus Q2 Ambient QAV DENVRNA13 Dengue Virus Q2 Ambient QAV JCBKDNA13 JC virus and BK virus Q2 Dry-ice QAP TGDNA13 Toxoplasma gondii Q3 Ambient QAB BbDNA13 Borrelia burgdorferi (Lyme's Disease) Q4 Dry-ice Congenital infection QAV CMVDBS13 Cytomegalovirus Dried Blood Spots Q2 Ambient QAP TGDNA13 Toxoplasma gondii Q3 Ambient Page 3 of 8
4 Drug Resistance QAB MRSADNA13 Methicillin Resistant S. aureus Q2 Ambient QAV ENVA13 HIV-1 Drug Resistance Q3 Ambient QAV ENVAINT13 HIV-1 Drug Resistance (Integrase) Q3 Ambient QAB ESBL13 Extended Spectrum ß-lactamase Q3 Dry-ice QAB VRE13 Vancomycin Resistant Enterococci Q3 Dry-ice QAB MRSASPA13 Methicillin Resistant S. aureus SPA Q3 Dry-ice QAV HBVDR13 HBV Drug Resistance Q3 Dry-ice QAV HCVDR13 HCV Drug Resistance Q3 Dry-ice Exotic QAV WNVRNA13 West Nile Virus Q2 Ambient QAV DENVRNA13 Dengue Virus Q2 Ambient Page 4 of 8
5 Gastro QAB CDDNA13 Clostridium difficile Q2 Ambient QAV ADVDNA13 Adenovirus Q4 Dry-ice QAV NVRNA13 Norovirus Q4 Dry-ice QAV GastroV13 Viral Gastroenteritis Q4 Dry-ice QAB GastroB13 Bacterial Gastroenteritis Q4 Dry-ice QAP GastroP13 Parasitic Gastroenteritis Q4 Dry-ice Immunocompromised QAV JCBKDNA13 JC virus and BK virus Q2 Dry-ice QAV HHV6DNA13 Human Herpes Virus 6 Q2 Dry-ice QAV CMVDNA13 Human Cytomegalovirus Q2 Dry-ice QAV CMVWB13 Human Cytomegalovirus Whole Blood Q2 Dry-ice QAV EBVDNA13 Epstein-Barr virus Q2 Dry-ice QAV EBVWB13 Epstein-Barr virus whole blood Q2 Dry-ice QAP TGDNA13 Toxoplasma gondii Q3 Ambient QAF ASPDNA13 Aspergillus Q4 Dry-ice QAF C.ALBDNA13 Candida albicans Q4 Dry-ice QAF PCPDNA13 Pneumocystis jirovecii pneumonia (PCP) Q4 Dry-ice Page 5 of 8
6 Respiratory QAB CP.MP13 Chlamydophila pneumoniae and Mycoplasma pneumoniae Q2 Ambient QAB LPDNA13 Legionella pneumophila Q2 Ambient QAB MTBDNA13 M. tuberculosis Complex Q3 Ambient QAB BPDNA13 Bordetella pertussis Q4 Dry-ice QAV ADVDNA13 Adenovirus Q4 Dry-ice QAV INFRNA13 Influenza A & B virus Q4 Dry-ice QAV MPV13 Human Metapneumovirus Q4 Dry-ice QAV RSV13 Respiratory Syncytial Virus Q4 Dry-ice QAV PINFRNA13 Parainfluenza virus Q4 Dry-ice QAV CVRNA13 Coronavirus Q4 Dry-ice QAV RVRNA13 Rhinovirus Q4 Dry-ice QAV INFHT13 Influenza Haemagglutinin Typing Q4 Dry-ice QAB CPS13 Chlamydia psittaci Q4 Dry-ice QAF PCPDNA13 Pneumocystis jirovecii pneumonia (PCP) Q4 Dry-ice Page 6 of 8
7 Sexually Transmitted infections QAB CTDNA13A Chlamydia trachomatis A Q1 Ambient QAV HSVDNA13 Herpes simplex virus 1& 2 Q1 Ambient QAB CTDNA13B Chlamydia trachomatis B Q2 Ambient QAB NgDNA13 Neisseria gonorrhoeae Q2 Ambient QAV HPVDNA13 Human Papillomavirus Q3 Ambient / Specialist* Transplant QAV JCBKDNA13 JC virus and BK virus Q2 Dry-ice QAV HHV6DNA13 Human Herpes Virus 6 Q2 Dry-ice QAV CMVDNA13 Human Cytomegalovirus Q2 Dry-ice QAV CMVWB13 Human Cytomegalovirus Whole Blood Q2 Dry-ice QAV EBVDNA13 Epstein-Barr virus Q2 Dry-ice QAV EBVWB13 Epstein-Barr virus whole blood Q2 Dry-ice QAP TGDNA13 Toxoplasma gondii Q3 Ambient QAV ADVDNA13 Adenovirus Q4 Dry-ice Page 7 of 8
8 Typing QAV HCVGT13 HCV Genotyping Q1 Dry-ice QAV HBVGT13 HBV Genotyping Q1 Dry-ice QAB MRSATP13 Methicillin Resistant S. aureus Typing Q2 Ambient QAV ENVA13 HIV-1 Drug Resistance Q3 Ambient QAV ENVAINT13 HIV-1 Drug Resistance (Integrase) Q3 Ambient QAB MRSASPA13 Methicillin Resistant S. aureus SPA Q3 Dry-ice QAV HBVDR13 HBV Drug Resistance Q3 Dry-ice QAV HCVDR13 HCV Drug Resistance Q3 Dry-ice QAV INFHT13 Influenza Haemagglutinin Typing Q4 Dry-ice QAB MALDIBAC13 MALDI-TOF Bacterial Q4 Dry-ice New EQA Pilot Studies for 2013 QAV EBVWB13 Epstein-Barr virus whole blood Q2 Dry-ice QAB ESBL13 Extended Spectrum ß-lactamase Q3 Dry-ice QAB VRE13 Vancomycin Resistant Enterococci Q3 Dry-ice QAB MRSASPA13 Methicillin Resistant S. aureus SPA Q3 Dry-ice QAV HCVDR13 HCV Drug Resistance Q3 Dry-ice QAB CPS13 Chlamydia psittaci Q4 Dry-ice Page 8 of 8
Version number CAT 2016/01
Version number CAT 2016/01 Contents An Introduction to the QCMD EQA Schemes 4 Disease Groups Blood Borne Virus 5 Central Nervous System 5 Congenital Infections 6 Drug Resistance 6 Exotic/Emerging Diseases
Version number CAT2018/02
www.qcmd.org Version number CAT2018/02 Contents An Introduction to the QCMD EQA Schemes 5 EQA Groups Blood Borne Virus 6 Central Nervous System 6 Congenital Infections 7 Drug Resistance 7 Exotic/Emerging
EQA PROGRAMME CATALOGUE. Version number CAT2019/01
2019 EQA PROGRAMME CATALOGUE www.qcmd.org Version number CAT2019/01 Contents An Introduction to the QCMD EQA Schemes 5 EQA Groups Blood Borne Virus 6 Central Nervous System 6 Congenital Infections 7 Drug
QUALITY CONTROL for MOLECULAR DIAGNOSTICS Quality issues highlighted through international external quality assessment
QUALITY CONTROL for MOLECULAR DIAGNOSTICS Quality issues highlighted through international external quality assessment William G MacKay PhD Neutral Office Coordinator QCMD The Altum Building, Todd Campus
Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections.
In the name of God Principles of post Tx infections 1: Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections. Infection processes can progress
Fifteen years of molecular EQA: progress and challenges
Fifteen years of molecular EQA: progress and challenges Anton M van Loon 1, Stuart West 2 and Paul Wallace 2 1 Department of Virology, UMC Utrecht, The Netherlands 2 QCMD, Glasgow, Scotland Key Issues
Test Requested Specimen Ordering Recommendations
Microbiology Essentials Culture and Sensitivity (C&S) Urine C&S Catheter Surgical (excluding kidney aspirates) Voided Requisition requirements o Specific method of collection MUST be indicated o Indicate
Microbiology EQA Product Portfolio
Labquality EQAS Microbiology EQA Product Portfolio Clinically relevant external quality assessment program for microbiology Bacterial serology Bacteriology Mycology Parasitology Preanalytics Virology Labquality
Corporate Medical Policy
Corporate Medical Policy Identification of Microorganisms Using Nucleic Acid Probes File Name: Origination: Last CAP Review: Next CAP Review: Last Review: identification_of_microorganisms_using_nucleic_acid_probes
Non-reproductive tissues and cells
Colour key Tested pathogen VIRAL Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legy binding on national level More stringent testing - recommended on national level Not
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding on national level More stringent - recommended on national level Not legy binding and not recommended on
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Royal Liverpool & Broadgreen University Hospitals NHS Trust Department of Virology Liverpool Clinical Laboratories Royal Liverpool and Broadgreen
M O L E C U L A R G E N E T I C S
MOLECULAR GENETICS ADVANTAGES OF MOLECULAR GENETICS Molecular genetics is a dynamic and transformative area of diagnostics, leading to insights in research and treatment in many disease states that are
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Tested pathogen Donor test/ technique
AMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS
AMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS Take Control, Molecular Control. 02 04 05 06 06 07 08 08 AMPLIRUN TOTAL RESPIRATORY INFECTIONS TUBERCULOSIS INFECTIONS GASTROINTESTINAL
DEPARTMENT OF MICROBIOLOGY IMPORTANT NOTICE TO USERS Turnaround Times (TATs) for Microbiology Investigations
Dear User, ISSUE: M008 DEPARTMENT OF MICROBIOLOGY IMPORTANT NOTICE TO USERS Turnaround Times (TATs) for Microbiology Investigations In order to comply with national quality guidance and as part of our
INFECTIOUS DISEASE. Page 2
Infectious disease Advantages OF TESTING INFECTIOUS DISEASE We are in the middle of a paradigm shift in infectious disease diagnostic testing. As we move from targeted infectious disease testing to a syndromic
Potential Reimbursement CPT Codes
BioFire FilmArray Blood Culture Identification (BCID) Panel Medicare All targets (n) 87150 n x * *BioFire BCID Panel is comprised of 27 total targets. The number of targets allowed for reimbursement may
Infection Control Manual Residential Care Part 3 Infection Control Standards IC6: Additional Precautions
IC6: 0110 Appendix I Selection Table Infection Control Manual esidential Care IC6: Additional Legend: outine Practice * reportable to Public Health C - Contact ** reportable by Lab D - Droplet A - Airborne
Laboratory Evidence of Human Viral and Selected Non-viral Infections in Canada
Canada Communicable Disease Report ISSN 1188-4169 Date of publication: October 1998 Volume 24S7 Supplement Laboratory Evidence of Human Viral and Selected Non-viral Infections in Canada 1989 to 1996 Our
MENU PRODUCT MOLECULAR. International Product Listing. Simplexa Molecular Kits Integrated Cycler Molecular Reagents and Primer Pairs
International Product Listing MOLECULAR PRODUCT MENU Simplexa Molecular Kits Integrated Cycler Molecular Reagents and Primer Pairs Products are not intended for donor screening. Simplexa Molecular Kits
Chain of Infection Agent Mode of transmission Contact (direct, indirect, droplet spread) Airborne Common-vehicle spread Host
Goals Microbiology of Healthcare-associated Infections William A. Rutala, Ph.D., M.P.H. Director, Statewide Program for Infection Control and Epidemiology and Research Professor of Medicine, University
Development and evaluation of user-developed protocols for bacterial respiratory pathogens leveraging the snap-load-go workflow of BD MAX TM
PAMM FOUNDATION LABORATORY FOR PATHOLOGY AND MEDICAL MICROBIOLOGY Development and evaluation of user-developed protocols for bacterial respiratory pathogens leveraging the snap-load-go workflow of BD MAX
Perform Gram stain only. Select Survey D5, Gram Stain
www.cap.org Bacteriology This flowchart is provided as a guide for ordering the appropriate Bacteriology Surveys for your laboratory s testing menu. In order to meet CLIA requirements for the subspecialty
Update on the development of clinical diagnostic run controls at NIBSC. Neil Almond Division of Virology
Update on the development of clinical diagnostic run controls at NIBSC Neil Almond Division of Virology BACKGROUND Molecular techniques are increasingly being used for microbiological diagnoses Assays
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legy binding on national level More stringent testing - recomd on national level Not legy binding and not recomd
BactoReal Kits for detection of bacteria
BactoReal Kits for detection of bacteria BactoReal Kit Bartonella spp. Detection of the glta gene of B. clarridgeiae, B. elizabethae, B. grahamii, B. henselae, B. koehlerae, B. quintana, B. volans and
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legally binding More stringent - recommended Not legally binding and not recommended Non-reproductive tissues and cells
Infectious Disease Antibodies and Antigens. ...Viro Stat. Supplying Researchers and Manufacturers Since
Infectious Disease Antibodies and Antigens...Viro Stat Supplying Researchers and Manufacturers Since 1985 Infectious Disease Antibodies and Antigens...Viro Stat Supplying Researchers and Manufacturers
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC and its technical Directives (particularly 2006/17/EC) More stringent -legally binding, applies for all donations and all donor profiles
Types of infections & Mode of transmission of diseases
Types of infections & Mode of transmission of diseases Badil dass Karachi King s College of Nursing Types of Infection Community acquired infection: Patient may acquire infection before admission to the
Non-reproductive tissues and cells
Ministry of Health: Institute for Transplantation and Biomedicine / Colour key VIRAL HIV 1 and HIV 2 Hepatitis B Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More
BEIPH Final Report. EQA Programme 2011 Chlamydia trachomatis (CTDNA11A) William G Mackay on behalf of QCMD and its Scientific Council April 2011
BEIPH Final Report EQA Programme 2011 Chlamydia trachomatis (CTDNA11A) William G Mackay on behalf of QCMD and its Scientific Council April 2011 Not to be reproduced or quoted without permission of QCMD.
CAVIWIPES1. Technical Bulletin
CAVIWIPES1 Technical Bulletin CaviWipes1 Disinfecting Towelettes are non-woven disposable towelettes pre-saturated with CaviCide1. CaviWipes 1 are intended for use in health care settings such as hospitals,
"Wanted Poster" Diseases
"Wanted Poster" Diseases Part One - Choosing a Disease Listed below are several bacteria and the disease they cause. Pick any one bacteria/disease to research. It is highly recommended that you pick a
Hepatitis C Virus (RNA)A
Hepatitis C Virus (RNA)A 2012 EQA Programme Final Report QAV994112 (HCVRNA12A) Professor Jacques Izopet Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2012 A UKAS accredited
Cleaning for Additional Precautions Table symptom based
for Additional Precautions Table symptom based The need to wear personal protective equipment () for Routine Practices is dependent on the risk of contact or contamination with blood or body fluids. should
Infection Data: Form Updates
Infection Data: Form Updates Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Why is infection data important?
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Microbiology Department Contact: Dr David Ashburn Zone 3 Raigmore Hospital Tel: +44 (0) 1463 704108 Old Perth Road Fax: +44 (0) 1463 705648
MOLECULAR DIAGNOSTIC PANELS and REAGENT KITS for NUCLEIC ACID EXTRACTION and RT-PCR of INFECTIOUS DISEASES and GENOMICS. Sep 2018
MOLECULAR DIAGNOSTIC PANELS and REAGENT KITS for NUCLEIC ACID EXTRACTION and RT-PCR of INFECTIOUS DISEASES and GENOMICS Sep 2018 STANDARDISED & EASY APPROACH TO PCR DIAGNOSTICS The diagnostic kits of MOLgen
ON O C N O C H O E H M E A M T A O T L O O L G O Y
REAL TIME PCR KITS von AB Analitica www.bioproducts.at ONKOHÄMATOLOGIE INFEKTIOLOGIE HUMANGENTIK CE IVD gleiches PCR Protokoll REALQUALITY CATALOGUE REALQUALITY REAL TIME PCR KITS Characteristics: CE IVD
At the forefront of multiplex PCR
Prodesse At the forefront of multiplex PCR 2005 PRODUCT CATALOG Distributed by Standard Format Assays Real Time Format Assays Hexaplex Influenza A Influenza B Parainfluenza 1 Parainfluenza 2 Parainfluenza
BEIPH Final Report. EQA Programme 2011 Chlamydia trachomatis B (CTDNA11B) Prepared on behalf of QCMD and its Scientific Council October 2011
BEIPH Final Report EQA Programme 2011 Chlamydia trachomatis B (CTDNA11B) Prepared on behalf of QCMD and its Scientific Council October 2011 Not to be reproduced or quoted without permission of QCMD. Any
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legally binding on national level More stringent testing - recommended on national level Not legally binding
Innovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays
About the author Disclaimer EXECUTIVE SUMMARY Molecular diagnostic technologies Healthcare-associated infections Sexually transmitted HPVs HIV and hepatitis viruses Market outlook and forecasts Molecular
Flu adenovirus h1n1 h3n2 h5n1 ah1n1
Influenza influenza Flu adenovirus h1n1 h3n2 h5n1 ah1n1 Gastroenteritis Gastroenteritis stomach flu gastroenteritides gastroenterities food poisoning campylobacter colitis gastroenterocolitis gastrointestinal
Increase in Locally-Acquired Cyclosporiasis Cases in Ontario
Increase in Locally-Acquired Cyclosporiasis Cases in Ontario Update to York Region health care providers as of July 31, 2018 Ontario is experiencing an increase in the number of Cyclospora infections.
Chlamydia trachomatis
Chlamydia trachomatis 2012 EQA Programme A Final Report QAB004101 (CTDNA12A) Dr Anton M van Loon Scientific Experts on behalf of QCMD Report authorised by the QCMD Executive in May 2012 A UKAS accredited
PAMET Continuing Education 2016
PAMET Continuing Education 2016 Agent of gastroenteritis Medium/method] used for routine screening/detection in stool samples Salmonella, Shigella, MacConkey, Hektoen, Bismuth sulfite,etc. Plesiomonas
Chlamydia trachomatis
Chlamydia trachomatis 2012 EQA Programme A Final Report QAB004101 (CTDNA12A) Version 2 Dr Anton M van Loon Scientific Experts on behalf of QCMD Report authorised by the QCMD Executive in May 2012 A UKAS
BEIPH Final Report. QCMD 2009 Neisseria gonorrhoeae (NGDNA09) EQA Programme
QUALITY CONTROL for MOLECULAR DIAGNOSTICS Block 4, Kelvin Campus, West of Scotland Science Park, Glasgow, G20 0SP Scotland Tel: +44 (0) 141 945 6474 Fax: +44 (0) 141 945 5795 www.qcmd.org info@qcmd.org
RESPIRATORY WATCH Week 3 (January 14 to January 20, 2018)*
Number of positive specimens RESPIRATORY WATCH Week (January to January, )* IN SUMMARY Activity levels** Zones, & are reporting localized activity. The is no activity being reported in Zone. There have
Schedule of Accreditation
Schedule of Accreditation Organisation Name National Virus Reference Laboratory INAB Reg No 326MT Contact Name Eimear Malone Address University College Dublin, Belfield, Dublin Contact Phone No 01-7161319
Syndromic Testing: The right test, the first time.
Syndromic Testing: The right test, the first time. Don t guess. Know. Infectious disease diagnostics has evolved. BioFire s syndromic approach is making the world a healthier place. Many infectious diseases
The use of QCMD proficiency testing panels in clinical virology.
The use of QCMD proficiency testing panels in clinical virology. Prof.dr. Bert Niesters Department of Medical Microbiology Division of Clinical Virology UMC Groningen Disease Disease Management Viral Load
RESPIRATORY WATCH Week 2 (January 6, 2019 to January 12, 2019 )*
Number of positive specimens RESPIRATORY WATCH Week (January, to January, )* IN SUMMARY Activity levels** Central and Western Zones have localized activity. Northern and Eastern Zones are reporting sporadic
EFFICACY SUMMARY FOR OXIVIR Tb. EPA Reg. No TGA Registration AUST R
Diversey Australia Pty Limited ABN 92 080 527 117 29 Chifley Street, Smithfield NSW 2164 Locked Bag 61 Wetherill Park NSW 2164 Australia Tel: 02 9757 0300 or 1800 647 779 Fax: 02 9725 5767 or 1800 626
Update of the CDC/HICPAC Guideline: Infection Prevention in Healthcare Personnel
Update of the CDC/HICPAC Guideline: Infection Prevention in Healthcare Personnel David T. Kuhar, M.D. Medical Epidemiologist HICPAC Meeting June 6, 2013 National Center for Emerging and Zoonotic Infectious
Clinical Microbiology CLS 2019 Clinical Microbiology Laboratory Scheme Application Form
Laboratory Scheme Application Form complete all sections below and return to LGC Standards Proficiency Testing by email, fax or post. Returning customer Lab ID: Purchase order no.: (compulsory) Round Despatch
Section 1 has been repealed by Decree of 30 December 2003/1383.
Ministry of Social Affairs and Health, Finland Unofficial translation No. 786/1986 Communicable Diseases Decree Issued on 31 October 1986 Section 1 has been repealed by Decree of 30 December 2003/1383.
KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Hospital Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK West of Scotland Specialist Virology Centre New Lister Building Level 5 Glasgow Royal Infirmary 10-16 Alexandra Parade Glasgow G31 2ER Contact:
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS APRIL 2017 Infectious viruses are a global health threat Since the approval of the first antiviral drug
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legally binding on national level More stringent testing - recommended on national level Not legally binding
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1 Infectious viral pathogens are a significant global health threat to mankind 2 Since the approval
Validation FTD Respiratory pathogens 33
Validation FTD Respiratory pathogens 33 32 reactions (catalog no. FTD-2P.3-32) 64 reactions (catalog no. FTD-2P.3-64) Qualitative assay for in vitro diagnostics Validated with: Applied Biosystems 7500
Ministry of Social Affairs and Health, Finland N.B. Unofficial translation. Legally valid only in Finnish and Swedish
Ministry of Social Affairs and Health, Finland N.B. Unofficial translation. Legally valid only in Finnish and Swedish No. 786/1986 Communicable Diseases Decree Issued on 31 October 1986 Section 1 was repealed
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 50, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 39, 2018 (Notification
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Public Health England, an executive agency of the Department of Health Clinical Microbiology and Public Health Laboratory Box 236, Addenbrookes Hospital Cambridge Biomedical Campus Hills Road Cambridge
Respiratory Pathogen Panel TEM-PCR Test Code:
Respiratory Pathogen Panel TEM-PCR Test Code: 220000 Tests in this Panel Enterovirus group Human bocavirus Human coronavirus (4 types) Human metapneumovirus Influenza A - Human influenza Influenza A -
Infections in immunocompromised host
Infections in immunocompromised host Immunodeficiencies Primary immunodeficiencies Neutrophil defect Humoral: B cell defect Humoral: Complement Cellular: T cells Combined severe immunodeficiency Secondary
Pneumonia Aetiology Why is it so difficult to distinguish pathogens from innocent bystanders?
Pneumonia Aetiology Why is it so difficult to distinguish pathogens from innocent bystanders? David Murdoch Department of Pathology University of Otago, Christchurch Outline Background Diagnostic challenges
Laboratory Survey Results. Preventing disease, promoting and protecting health
Laboratory Survey Results Laboratory Survey 211 1 Bacteriology Laboratory Capacity in Twenty (2) CMC Percentage% Capacity 8 6 4 2 Campylobacter Cholera E. coli Leptospirosis N. meningitidis H. influenzae
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Non-reproductive tissues and cells VIRAL
FEDERAL PUBLIC SERVICE, HEALTH, FOOD CHAIN SECURITY AND ENVIRONMENT CLINICAL BIOLOGY COMMISSION CLINICAL BIOLOGY SECTION
IPH J. Wytsmanstreet 14 B-1050 Brussels FEDERAL PUBLIC SERVICE, HEALTH, FOOD CHAIN SECURITY AND ENVIRONMENT CLINICAL BIOLOGY COMMISSION CLINICAL BIOLOGY SECTION External Quality Assessment for Molecular
IP Lab Webinar 8/23/2012
2 What Infection Preventionists need to know about the Laboratory Anne Maher, MS, M(ASCP), CIC Richard VanEnk PhD, CIC 1 Objectives Describe what the laboratory can do for you; common laboratory tests
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Issue No: 001 Issue date: 28 September 2018 Department of Microbiology Contact: Diane Matley Level B Tel: +44 (0)23 8120 6408 Pathology Block E-Mail: Diane.Matley@uhs.nhs.uk Southampton General Hospital
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 38, 2018 (Notification
CAVIWIPES. Technical Bulletin
CAVIWIPES Technical Bulletin CaviWipes Disinfecting Towelettes are non-woven disposable towelettes pre-saturated with CaviCide. CaviWipes are intended for use in health care settings such as hospitals,
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 49, 2018 (Notification
PATHOGEN DETECTION WITH THE FILMARRAY
PATHOGEN DETECTION WITH THE FILMARRAY The System Sample-to-Answer in an Hour Single sample Multiple samples The FilmArray integrates sample preparation, amplification, detection, and analysis all into
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 33, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 3, 2019 (Notification
Pre-Assessment Review: Microbiology, Part 2: Virology. Dr. David Hillyard
Pre-Assessment Review: Microbiology, Part 2: Virology Dr. David Hillyard 1. Mutations or deletions within which gene are associated with the hyper-toxin producing strain of Clostridium difficile? a. tcda
About HPV. Human papillomavirus (HPV) is a group of viruses that are extremely common worldwide. Theree are more than 100 types of HPV, of which at
Cervical Cancer & HPV What is HPV Human papillomavirus (HPV) is a group of viruses that are extremely common worldwide. About HPV Theree are more than 100 types of HPV, of which at least 13 are cancer-causing
Storage conditions. roomtemperature or incubator at 36 C. Other: 2-8 C Blood: roomtemperature or incubator at. A.s.a.p. max 24h. A.s.a.p.
Extract Vademecum Department of Medical Microbiology Status: Code: Version: Approval date: Geldig MMB-PR-04/1 1 Juni 2017 Name request Specimen Material needed Transport Bacteriology Bacterial culture
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 22, 2018 (Notification
About the LIAISON MDX
The quality of treatment starts with diagnosis International Molecular Product MENU Simplexa Molecular Kits LIAISON MDX Molecular Reagents Primer Pairs About the LIAISON MDX The LIAISON MDX is an innovative
Isolation Precautions in Clinics
Purpose Audience General principles Possible Exposures To define isolation precautions in a clinic setting. Clinics Isolation status should be determined primarily by the suspected disease and/or pathogen.
Robert Van Exan, Ph.D President: Immunization Policy & Knowledge Translation. 3/22/2016 R Van Exan: Immunization Policy & Knowledge Translation 1
Robert Van Exan, Ph.D President: Immunization Policy & Knowledge Translation 3/22/206 R Van Exan: Immunization Policy & Knowledge Translation Disclosure Statement Disclosure of Relationship I am a member
B19 Virus EQA Programme Final Report QAV (B19DNA14)
B19 Virus 2014 EQA Programme Final Report QAV034116 (B19DNA14) Prof. Hubert GM Niesters Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2014 A UKAS accredited proficiency
Viral Diseases. T Bamdad, PhD, Tarbiat Modares University
Viral Diseases 1 Categorizing viral infections by the organ system most commonly affected (eg, lungs, GI tract, skin, liver, CNS, mucous membranes) can be clinically useful, although certain viral disorders
FERTISAFE PLUS US PL AFE TIS FER
FERTISAFE PLUS FERTISAFE PLUS FERTISAFE PLUS Broad Spectrum Antimicrobial Disinfectant Fertisafe Plus is a long lasting, CE marked, ready to use broad spectrum antimicrobial disinfectant. Quaternary Ammonium
A Cost-Effective Interdisciplinary Approach to Microbiologic Send-Out Test Use
A Cost-Effective Interdisciplinary Approach to Microbiologic Send-Out Test Use Scott W. Aesif, MD, PhD; David M. Parenti, MD; Linda Lesky, MD; John F. Keiser, MD, PhD Context. Use of reference laboratories
Infectious Diseases Weekly Report. 14 March 2013 / Number 10
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 14 March / Number 10 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Luton and Dunstable University Hospital NHS Foundation Trust Lewsey Road Luton Bedfordshire LU4 0DZ Contact: Pauline Philip Tel: +44 (0)1582
Orientation Program for Infection Control Professionals
Orientation Program for Infection Control Professionals Module 7: Communicable Diseases Table of Contents Module 7: Communicable Diseases... 1 Objectives... 1 Instructions... 1 Overview... 2 Key Concepts...
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Derriford Hospital Derriford Road Plymouth PL6 8DH Contact: John Hooper Tel: +44 (0) 1752 792369 E-Mail: johnhooper@nhs.net Website: www.plymouthhospitals.nhs.uk/pathologywelcome
Manitoba Monthly Surveillance Unit Report
Manitoba Monthly Surveillance Unit Report Reported up to June 30, 2012 Highlights: 1. Antimicrobial Resistant Organisms Together Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile